Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

BARDA-CBRN-BAA-11-100-SOL-00009

Solicitation Number: BARDA-CBRN-BAA-11-100-SOL-00009
Agency: Department of Health and Human Services
Office: Office of the Secretary
Location: Acquisitions Management, Contracts, & Grants (AMCG)
  • Print

Note:

There have been modifications to this notice. To view the most recent modification/amendment, click here
:
BARDA-CBRN-BAA-11-100-SOL-00009
:
Award
:
Added: Feb 18, 2011 4:59 pm
BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of CBRN agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.


In addition, the Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development (ii) research on and development of research tools and other devices and technologies and (iii) research to promote strategic initiations. The PAHPA is also located on the ASPR website: http://www.phe.gov/about/amcg/ard/Pages/default.aspx.



The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.


Research Areas of Interest:


1. Vaccines Development
2. Antitoxins and Therapeutics
3. Antimicrobials and Antivirals
4. Radiological and Nuclear Agent Countermeasures
5. Chemical Agent Countermeasures
6. Diagnostics



BARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).


The Government intends to have a full & open competition for this requirement in the form of a BAA. This synopsis is not a BAA; a BAA is anticipated on March 4, 2011. The Government expects to make 1 or more awards, subject to the availability of funds, on or about September 16, 2011.


 


Contact Information:


Comments to this announcement, referencing synopsis BARDA-CBRN-BAA-11-100-SOL-00009 may be submitted to CBRN-BAA-11@hhs.gov



Pre-proposal Conference:


A pre-proposal conference will be held on March 23rd, 2011 from 2-4 pm at the following address:


200 Independence Avenue S.W.
Hubert H Humphrey Building 7th floor Room 725A
Washington, DC 20201


Please note the following regarding the pre-proposal conference:


1. Enter the Humphrey Building at the Independence Avenue Street entrance.
2. Arrive 30 minutes early to allow time to clear security.
3. Bring a state-issued form of identification.*
4. The closest metro stop is Federal Center SW
5. Attendance is limited to a maximum of two (2) people per company. Email the names of your attendees to CBRN-BAA-11@hhs.gov by Friday, March 11, 2011.
6. Tape recorders and videos are prohibited.
7. Presentation material from the conference will be posted on FedBizOpps in an amendment to the BAA following the pre-proposal conference


* Be advised that in order to obtain security clearance, advanced notification must be provided by all attendees who are not United States citizens.



Pre-proposal Conference #2: A second pre-proposal conference is anticipated on or about June 8, 2011 in San Diego, CA and will be announced in a subsequent FedBizOpps amendment to this BAA.


Questions from industry regarding the Special Instruction B (announced in a subsequent FedBizOpps amendment) may be emailed to CBRN-BAA@hhs.gov no later than March 15, 2011. Submitted questions will be addressed during the March 23rd Pre-Proposal Conference.


NOTE: For those unable to attend, you may choose to dial-in and still participate in the conference. Please notify us of your interest in this option and use the following dial-in information: 1-800-369-2101 Participant code # 45746.

Added: May 18, 2011 1:52 pm Modified: May 20, 2011 10:34 amTrack Changes
 BARDA-CBRN-BAA-11-100-SOL-00009
Added: Feb 03, 2012 10:45 am
Thermal Burn Special Instructions
Added: Feb 22, 2012 3:13 pm
Slides for the Jan 23 2012 Pre-Proposal Conference for the Thermal Burn amendment to this soliciation.
Added: Oct 11, 2012 1:13 pm
This announcement is for the award of a Cost Plus Fixed Fee (CPFF) type R&D contract to Velico Medical, Inc. for the development of a system to spray dry plasma, under the procedures of the subject Broad Agency Announcement (BAA).
Added: Oct 18, 2012 8:46 am
The purpose of this contract is to develop a product that will combine the wound healing properties of the Celution System, which has been developed by the contractor, with a cell-friendly dressing as a medical countermeasure for use in the context of combined injury and radiation exposure, and to obtain FDA licensure for the Celution System with indications for use that explicitly include thermal burn.
Added: Jun 24, 2013 5:33 pm
The purpose of this announcement is for the award of a Cost Sharing/Cost Plus Fixed Fee type contract to Basilea Pharmaceutica International, Ltd. for the Research and Development of BAL30072, a novel monosulfactam for the treatment of infections caused by multi-drug resistant gram-negative bacterial pathogens.
Added: Sep 25, 2013 3:39 pm
The purpose of this contract to MRI Global is to conduct advanced development of PCR-based assays for the presumptive diagnosis of anthrax, plague, and tularemia using instrument platforms widely fielded in clinical laboratories. The system will address a major gap in the nation's ability to rapidly diagnose individuals suspected of being infected with Category A bacterial threat agents.
Added: Sep 30, 2013 10:38 am
This announcement is for the award of a Cost Plus Fixed Fee (CPFF) type R&D contract to Argentum Medical, LLC in support of seeking additional 510(k) FDA indications for Contractor's commercially available silver-nylon burn dressing product, Silverlon® (the "Product").The R&D effort includes animal studies to test the safety and efficacy of the Product when used to treat two types of injury: vesicant and radiation.
Please consult the list of document viewers if you cannot open a file.

Solicitation 1

Type:
Solicitation
Posted Date:
March 4, 2011
Description: BARDA-CBRN-BAA-11-100-SOL-00009

Presentation from Pre-proposal Meeting - 3/23/11

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
Presentation from Pre-proposal Meeting - 3/23/11
Posted Date:
March 23, 2011
Description: Slides presented at the pre-proposal meeting in Washington, DC, March 23, 2011.

Amendment 1

Type:
Mod/Amendment
Posted Date:
March 24, 2011
Description: Amendment #1 changes the point of contact for area of interest #5 (Chem).

West Coast Industry Day Information

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
West Coast Industry Day Information
Posted Date:
May 18, 2011
Description: West Coast BARDA Industry Day: Contracting for Countermeasures on June 7-9, 2011

Amendment 2

Type:
Mod/Amendment
Posted Date:
August 19, 2011
Description: Amendment #2 - Decorporation requirement description to AOI #4

Amendment 3

Type:
Mod/Amendment
Posted Date:
February 3, 2012
Description: Amendment #3

Package #7

Posted Date:
February 3, 2012
Description: The purpose of these special instructions is to solicit proposals for advanced development of existing and prospective medical products that improve ‘Definitive Care’ required for full-skin-thickness burn injuries or deep partial-skin-thickness burn injuries likely to convert to full-skin-thickness injuries. These instructions address treatments such as skin substitutes for thermal burn injuries likely to result from detonation of an improvised nuclear device (see Research Area 4 in the Broad Agency Announcement), recognizing that such treatments may be useful also for burns due to common causes (e.g., flames, scalds, chemicals). As a result, preparedness for a wide range of types of burn injuries, resulting from any cause, and importantly from any mass-casualty incident resulting in many thermal burns, may benefit from these product-development efforts.
Description: The Hosting Official/Organization must request approval for foreign visitation from PSC in advance of a proposed visit. This includes visits to any component, regional or field office, where a foreign national’s access to the facility or space is reviewed and authorized by the PSC Security Office. This form must be completed by all foreign nationals wishing to attend the pre-proposal conference. Please complete, sign, and submit the form no later than 12 business days prior to the February 23, 2012, meeting. Further information may be found in the last section of the Thermal Burn Special Instructions, entitled Pre-Proposal Conference, item number 6.

Slides for Thermal Burn Pre-Soliciation Meeting Jan 23 2012

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Label:
Slides for Thermal Burn Pre-Soliciation Meeting Jan 23 2012
Posted Date:
February 22, 2012
Description: Attached is the slide deck for the Pre-Proposal Conference for the Thermal Burn soliciation to this BAA. The conference is scheduled for Thursday, Jan 23, 2012,
:
Office of the Assistant Secretary for Preparedness & Response (ASPR)
Department of Health and Human Services
330 Independence Ave. SW
G640
Washington, District of Columbia 20201
United States
:
Contracting Office Mailing Address:

Office of Acquisitions Management, Contracts & Grants
330 Independence Avenue, SW, # G640
Washington, DC, 20201


United States
:
Matthew A. McCord,
Contract Specialist
Phone: 202.260.0689
:
Glynis Fisher,
Contracting Officer
Phone: 202.260.1880